Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Postprandial Regulation of Bone Perfusion in Healthy Individuals

NCT07679516 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-07-19
Last updated
2026-07-09

Condition(s) studied

Healthy Adult ParticipantsBone PhysiologyBone Blood Flow RegulationPeptide Hormones

Investigational drug(s) / intervention(s)

isotonic saline infusionInfusion of GIP(1-42)Infusion of GLP-2(1-33)Infusion of pramlintide

isotonic saline infusion: Placebo infusion for comparison of active hormone

Infusion of GIP(1-42): Study tool

Infusion of GLP-2(1-33): Study tool

Infusion of pramlintide: Study tool

Study summary

The goal of this clinical trial is to learn whether certain natural hormones - Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-2, (GLP-2), and amylin - affect blood flow to the bones.

Eligibility

Sex
ALL
Min age
25 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age 25-50 years. 2. BMI between 18.5-30 kg/m2. 3. Normal gait. 4. Premenopausal (if female). 5. Informed consent. Exclusion Criteria: 1. Bone disease incl. confirmed osteopenia. 2. Fracture within the last 6 months at the time of inclusion. 3. Amputation or congenital defect of extremities. 4. HbA1c\>41.9 mmol/mol and/or diagnosed type 1 or type 2 diabetes. 5. Any ongoing or prior medication that the investigator evaluates could interfere with the endpoints of the study (e.g. glucocorticoids or other medications that may compromise bone health). 6. Pregnancy or breastfeeding (or plans thereof within the study duration). 7. Not using effective hormonal contraceptives or an intra uterine device within study duration (e.g. oral contraceptives, transdermal patch, vaginal ring, Depo-Provera injections, Nexplanon implant). 8. Ongoing or prior alcohol abuse (defined per ICD-10 classification for alcohol dependence syndrome, F10.21) or daily alcohol intake 9. Use of any illicit substance or narcotics within three months of inclusion, including within study duration. 10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation. 11. Recent (three months prior to inclusion), ongoing or planned weight loss within study duration (weight loss defined as exceeding -5% bodyweight, or intentional hypocaloric dieting)

Primary outcome measure(s)

  • Median Ki in the Femur — 90 minutes
    Kinetic modelling

Trial sites (1)

FacilityCityRegionStatus
Rigshospitalet Copenhagen Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07679516 on ClinicalTrials.gov ↗ ← All trials in Denmark